Literature DB >> 1722245

A characterization of glycinergic receptors present in cultured rat medullary neurons.

C A Lewis1, Z Ahmed, D S Faber.   

Abstract

1. Whole-cell current responses to bath application of glycine, beta-alanine, and taurine were studied in medullary neurons cultured from embryonic rats. 2. Two current components were seen in the responses to bath application of agonist, one component that desensitized and another that did not. 3. The two current components have different dose-response characteristics, with the nondesensitizing component being activated more effectively at lower concentrations than the desensitizing component and also reaching its peak at lower concentrations. The agonist concentrations producing half-maximal responses are 26 +/- 4 (SE, n = 6) and 69 +/- 17 (n = 7) microM for the nondesensitizing and desensitizing components, respectively, for glycine; 54 +/- 7 (n = 9) and 127 +/- 37 (n = 7) microM for beta-alanine; and 153 +/- 24 (n = 9) 443 +/- 99 (n = 3) microM for taurine. Thus, for each component, the order of potency is glycine greater than beta-alanine greater than taurine. 4. When total responses to glycine, beta-alanine, and taurine are compared in the same cells, taurine and beta-alanine are less potent agonists than glycine, with relative potencies of 1:0.4:0.1 for glycine-beta-alanine-taurine. 5. The desensitizing component is more sensitive to strychnine than the nondesensitizing one. The strychnine concentrations that block 50% of the response to a control dose of agonist are 15 and 500 nM for the desensitizing and nondesensitizing components, respectively, for glycine; 60 nM and 1 microM for beta-alanine; and 18 and 500 nM for taurine. 6. The complete occlusion between the responses to glycine and beta-alanine or glycine and taurine suggests that these agonists activate the same receptors. 7. The two current components may be manifestations of one receptor population with complicated kinetics or two independent receptor populations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722245     DOI: 10.1152/jn.1991.66.4.1291

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  7 in total

1.  Potentiation of chloride responses to glycine by three 5-HT3 antagonists in rat spinal neurones.

Authors:  D Chesnoy-Marchais
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

2.  Partition of transient and sustained inhibitory glycinergic input to retinal ganglion cells.

Authors:  Y Han; J Zhang; M M Slaughter
Journal:  J Neurosci       Date:  1997-05-15       Impact factor: 6.167

3.  Effects of inhalational general anaesthetics on native glycine receptors in rat medullary neurones and recombinant glycine receptors in Xenopus oocytes.

Authors:  D L Downie; A C Hall; W R Lieb; N P Franks
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Assembly of the outer retina in the absence of GABA synthesis in horizontal cells.

Authors:  Timm Schubert; Rachel M Huckfeldt; Edward Parker; John E Campbell; Rachel O L Wong
Journal:  Neural Dev       Date:  2010-06-18       Impact factor: 3.842

5.  Residues within transmembrane segment M2 determine chloride conductance of glycine receptor homo- and hetero-oligomers.

Authors:  J Bormann; N Rundström; H Betz; D Langosch
Journal:  EMBO J       Date:  1993-10       Impact factor: 11.598

6.  Inhibitory glycinergic neurotransmission in the mammalian auditory brainstem upon prolonged stimulation: short-term plasticity and synaptic reliability.

Authors:  Florian Kramer; Désirée Griesemer; Dennis Bakker; Sina Brill; Jürgen Franke; Erik Frotscher; Eckhard Friauf
Journal:  Front Neural Circuits       Date:  2014-03-10       Impact factor: 3.492

7.  Signaling Pathway of Taurine-Induced Upregulation of TXNIP.

Authors:  Hideo Satsu; Yusuke Gondo; Hana Shimanaka; Masato Imae; Shigeru Murakami; Kenji Watari; Shunichi Wakabayashi; Sung-Joon Park; Kenta Nakai; Makoto Shimizu
Journal:  Metabolites       Date:  2022-07-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.